Listen Score
LS 41
Global Rank
TOP 1.5%

O TYM PODKAŚCIE 🔗

Częstotliwość aktualizacji:
biweekly
Średnia długość dźwięku:
45 minutes
Wywiady gościnne
Ma sponsorów
Język angielski
Stany Zjednoczone
310 odcinków
od 11 listopada 2020
episodic

NAJNOWSZY ODCINEK 🔗

The expensive decision rarely looks intelligent before the market needs it. Operators can build for the regulations in front of them, or for the direction regulators are already moving. Across global medical cannabis markets, internal labs, stability programs, EU GMP manufacturing, and control of d…

WYSZUKAJ MINIONE ODCINKI

Wyszukaj minione odcinki The Dime.

POPRZEDNIE ODCINKI

A 115-year farm discovered that preserving the legacy meant letting a new crop compete with it. Ayrloom reached Beak & Skiff's revenue scale in three years, then forced the family to reallocate capital, people, land, and drying space while cannabis regulation kept the businesses legally separat…
Federal cannabis reform is supposed to open the same door for everyone. The current market says otherwise. The largest operators do not share one political agenda, and some of the barriers they complain about are also widening their moats. As capital markets, international medical standards, and st…
Fast-acting edibles can command a premium, but labels such as "nano" do not prove the final product works. The larger operating question is whether the formulation improves taste, shelf stability, manufacturing efficiency, and trust at the same time. This week we sit down with Kim Sanchez Rael Fast…
Global expansion is often pitched as an opportunity. For an undisciplined cannabis company, it is an expensive way to expose every weakness at once. International markets reward specific operating capabilities, not ambition alone. Pharmaceutical standards, reliable supply, disciplined data use, and…
Much of the licensed cannabis industry is quietly counting the volume it expects to inherit from the federal hemp ban coming this November. ** Now December. What they may not realize is that the ban could eliminate the full-spectrum therapeutic hemp formulations that helped change America's view o…
AI has made software easier than ever to build. That does not mean every internal tool should become the backbone of your business. In this episode, Bryan sits down with Chris Guthrie to break down the growing temptation inside cannabis companies to vibe code internal tools, dashboards, CRMs, ERPs…
Cannabis rescheduling is not as simple as “Trump rescheduled cannabis.” States are interpreting rescheduling completely differently depending on their license structure. These tiny details are widening the gap between potential winners and losers. In this episode, we break down what actually chan…
Predictable cash flow is the whole game. In cannabis, predictable is the one thing almost nobody has. Organigram CEO James Yamanaka came up over 20 years at British American Tobacco, where that discipline is the entire model. He thinks the opportunity starts there: trim the portfolio, stop chasing…
When a regulator asks what the downside is of adding one more testing requirement, what is the downside? Just a little more safe. Just in case. Especially when adding one more item to an already exhaustive testing panel. That logic is how licensed cannabis markets end up buried under compliance la…
Zastrzeżenie: Podcast i grafika osadzone na tej stronie pochodzą z Bryan Fields, który jest własnością jego właściciela i nie jest powiązany ani wspierany przez Listen Notes, Inc.